Cargando…
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 hea...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502276/ https://www.ncbi.nlm.nih.gov/pubmed/22938027 http://dx.doi.org/10.1186/1477-7819-10-180 |
_version_ | 1782250302681907200 |
---|---|
author | Eser, Mehmet Kement, Metin Balin, Salim Coskun, Cihan Kefeli, Umut Gumus, Mahmut Altuntas, Yunus Emre Kurt, Necmi Mayadagli, Alparslan |
author_facet | Eser, Mehmet Kement, Metin Balin, Salim Coskun, Cihan Kefeli, Umut Gumus, Mahmut Altuntas, Yunus Emre Kurt, Necmi Mayadagli, Alparslan |
author_sort | Eser, Mehmet |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of disease were recorded. The same parameters, except stage of disease, were also recorded for the control group. Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups. Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the gastric cancer group. RESULTS: There were no statistical differences in any demographic variables (age, gender and BMI) between the groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group (73.3 ± 27.5) were statistically similar (P = 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P < 0.001). In the gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F 1 + 2 levels. CONCLUSION: In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer patients. |
format | Online Article Text |
id | pubmed-3502276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35022762012-11-21 Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer Eser, Mehmet Kement, Metin Balin, Salim Coskun, Cihan Kefeli, Umut Gumus, Mahmut Altuntas, Yunus Emre Kurt, Necmi Mayadagli, Alparslan World J Surg Oncol Research BACKGROUND: The purpose of this study was to investigate plasma levels of thrombin activatable fibrinolysis inhibitor (TAFI) and TAFI’s relationship with coagulation markers (prothrombin fragment 1 + 2) in gastric cancer patients. METHODS: Thirty-three patients with gastric adenocarcinoma and 29 healthy control subjects were prospectively enrolled in the study. Patients who had a history of secondary malignancy, thrombosis related disease, oral contraceptive use, diabetes mellitus, chronic renal failure or similar chronic metabolic disease were excluded from the study. A fasting blood sample was drawn from patients to determine the plasma levels of TAFI and Prothrombin Fragment 1 + 2 (F 1 + 2). In addition, data on patient age, sex, body mass index (BMI) and stage of disease were recorded. The same parameters, except stage of disease, were also recorded for the control group. Subsequently, we assessed the difference in the levels of TAFI and F 1 + 2 between the patient and control groups. Moreover, we investigated the relation of TAFI and F 1 + 2 levels with age, sex, BMI and stage of disease in the gastric cancer group. RESULTS: There were no statistical differences in any demographic variables (age, gender and BMI) between the groups (Table 1). The mean plasma TAFI levels of the gastric cancer group (69.4 ± 33.1) and control group (73.3 ± 27.5) were statistically similar (P = 0.62). The mean plasma F 1 + 2 level in the gastric cancer group was significantly higher than for those in the control group (549.7 ± 325.3 vs 151.9 ± 67.1, respectively; P < 0.001). In the gastric cancer group, none of the demographic variables (age, gender and BMI) were correlated with either TAFI or F 1 + 2 levels. Also, no significant associations were found between the stage of the cancer and either TAFI or F 1 + 2 levels. CONCLUSION: In our study, TAFI levels of gastric cancer patients were similar to healthy subjects. The results of our study suggest that TAFI does not play a role in pathogenesis of the hypercoagulable state in gastric cancer patients. BioMed Central 2012-08-31 /pmc/articles/PMC3502276/ /pubmed/22938027 http://dx.doi.org/10.1186/1477-7819-10-180 Text en Copyright ©2012 Eser et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Eser, Mehmet Kement, Metin Balin, Salim Coskun, Cihan Kefeli, Umut Gumus, Mahmut Altuntas, Yunus Emre Kurt, Necmi Mayadagli, Alparslan Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title_full | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title_fullStr | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title_full_unstemmed | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title_short | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
title_sort | is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502276/ https://www.ncbi.nlm.nih.gov/pubmed/22938027 http://dx.doi.org/10.1186/1477-7819-10-180 |
work_keys_str_mv | AT esermehmet isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT kementmetin isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT balinsalim isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT coskuncihan isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT kefeliumut isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT gumusmahmut isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT altuntasyunusemre isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT kurtnecmi isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer AT mayadaglialparslan isthereanyroleofthrombinactivatablefibrinolysisinhibitorinthedevelopmentofahypercoagulablestateingastriccancer |